RecruitingB-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Eligible age

18+ yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

Sponsor: ADC Therapeutics S.A.

You may qualify if…

✓ Male or female participant aged 18 years or older
✓ Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) B-NHL (2016 World Health Organization classification) who have failed, or been intolerant to any approved therapy and had received at least two systemic treatment regimens in Part 1; and at least one systemic treatment regimen in Part 2
✓ LBCL:
✓ Part 2 Arm E enrollment focused on LBCL only
✓ DLBCL, not otherwise specified (NOS)
✓ Germinal Center B-cell type
✓ Activated B-cell type
✓ Transformed FL (note: patients with transformed FL must have received at least one line of systemic therapy post-transformation to be eligible)

You may not qualify if…

✕ Known history of hypersensitivity resulting in treatment discontinuation to or positive serum human ADA to a CD19 antibody
✕ Previous therapy with loncastuximab tesirine
✕ Previous treatment with polatuzumab vedotin, glofitamab or mosunetuzumab (applied to relevant arm and/or cohort of the specific drug administered)
✕ Participants who received previous treatment of polatuzumab vedotin containing regimen will be excluded from Arm C
✕ Participants who received previous treatment of glofitamab containing regimen will be excluded from Arm E
✕ Participants who received previous treatment of mosunetuzumab containing regimen will be excluded from Arm F
✕ Human immunodeficiency virus (HIV) seropositive
✕ Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load